Modulation of intestinal barrier properties by probiotics: Role in reversing colitis

Annals of the New York Academy of Sciences

Volumn 1165, Issue , 2009, Pages 175-182

  Resta Lenert, Silvia C ^a   Barrett, Kim E ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Barrier function; Chloride secretion; Crohn's disease; Epithelium; Probiotics; Ulcerative colitis

Indexed keywords

PROBIOTIC AGENT;

ARTICLE; COLITIS; CROHN DISEASE; DRUG MECHANISM; ENTERITIS; INTESTINE; INTESTINE EPITHELIUM; ION TRANSPORT; LACTOBACILLUS ACIDOPHILUS; NONHUMAN; STREPTOCOCCUS THERMOPHILUS; ULCERATIVE COLITIS;

ANIMALIA;

EID: 67249115274     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04042.x     Document Type: Article

References (37)

1. Chan, L.M.S., S. Lowes & B.H. Hirst. 2004. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur. J. Pharm. Sci. 21: 25-51.
2. Kaunitz, J.D., K.E. Barrett & J.A. McRoberts. 1995. Electrolyte secretion and absorption: small intestine and colon. In Textbook of Gastroenterology. T. Yamada, Ed.: 326-361. J.B. Lippincott Company. Philadelphia.
3. Tappenden, K.A. & A.S. Deutsch. 2007. The physiological relevance of the intestinal microbiota - contributions to human health. J. Am. Coll. Nutr. 26: 679S- 683.
4. Eckburg, P.B., E.M. Bik, C.N. Bernstein, et al. 2005. Diversity of the human intestinal microbial flora. Science 308: 1635-1638.
5. Gill, S.R., M. Pop, R.T. Deboy, et al. 2006. Metagenomic analysis of the human distal gut microbiome. Science 312: 1355-1359.
6. Stecher, B. & W.D. Hardt. 2008. The role of microbiota in infectious disease. Trends Microbiol. 16: 107-114.
7. Sartor, R.B. 2008. Microbial influences in inflammatory bowel diseases. Gastroenterology 134: 577-594.
8. Shanahan, F. 2005. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease. Am. J. Physiol. Gastrointest. Liver Physiol. 288: G417- G421.
9. Jonkers, D.S.R. 2007. Probiotics in gastrointestinal and liver diseases. Aliment. Pharmacol. Ther. 26(Suppl 2): 133-148.
10. Cabana, M.D., M. McKean, A.R. Wong, et al. 2007. Examining the hygiene hypothesis: the trial of infant probiotic supplementation. Paediatr. Perinat. Epidemiol. 21(Suppl 2): 23-28.
11. Nikfar, S., R. Rahimi, F. Rahimi, et al. 2008. Efficacy of probiotics in irritable bowel syndrome: a meta- analysis of randomized, controlled trials. Diseases of the Colon and Rectum 51: 1775-1780.
12. So, J.S., H.K. Kwon, C.G. Lee, et al. 2008. Lactobacillus casei suppresses experimental arthritis by down-regulating T helper 1 effector functions. Mol. Immunol. 45: 2690-2699.
13. Levy, S.E. & S.L. Hyman. 2005. Novel treatments for autistic spectrum disorders. Ment. Retard. Dev. Disabil. Res. Rev. 11: 131-142.
14. Montrose, M.H., S.J. Keely & K.E. Barrett. 2003. Electrolyte secretion and absorption: small intestine and colon. In Textbook of Gastroenterology. T. Yamada, Ed.: 308-339. Lippincott Williams and Wilkins. Philadelphia.
15. Zeissig, S., T. Bergann, A. Fromm, et al. 2008. Altered ENaC expression leads to impaired sodium absorption in the noninflamed intestine in Crohn's disease. Gastroenterology 134: 1436-1447.
16. Zeissig, S., N. Burgel, D. Gunzel, et al. 2007. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut 56: 61-72.
17. Sturm, A. & A.U. Dignass. 2008. Epithelial restitution and wound healing in inflammatory bowel disease. World J. Gastroenterol. 14: 348-353.
18. Clayburgh, D.R., L. Shen & J.R. Turner. 2004. A porous defense: the leaky epithelial barrier in intestinal disease. Lab. Invest. 84: 282-291.
19. Meddings, J. 2000. Barrier dysfunction and Crohn's disease. Ann. N. Y. Acad. Sci. 915: 333-338.
20. +-ATPase in ulcerative colitis. J. Pathol. 204: 84-92.
21. McCole, D.F., G. Rogler, N. Varki & K.E. Barrett. 2005. Epidermal growth factor partially restores colonic ion transport responses in mouse models of chronic colitis. Gastroenterology 129: 591-608.
22. Resta-Lenert, S. & K.E. Barrett. 2003. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut 52: 988-997.
23. Resta-Lenert, S. & K.E. Barrett. 2006. Probiotics and commensals reverse TNF-alpha- and IFN-gamma-induced dysfunction in human intestinal epithelial cells. Gastroenterology 130: 731-746.
24. Lencer, W.I., G. Cheung, G.R. Stroheimer, et al. 1997. Induction of epithelial chloride secretion by channel-forming cryptdins 2 and 3. Proc. Natl. Acad. Sci. USA 94: 8585.
25. Zamuner, S.R., N. Warrier, A.G. Buret, et al. 2003. Cyclooxygenase 2 mediates post-inflammatory colonic secretory and barrier dysfunction. Gut 52: 1714-1720.
26. Besancon, F., G. Przewlocki, I. Baro, et al. 1994. Interferon-gamma downregulates CFTR gene expression in epithelial cells. Am. J. Physiol. 267: C1398- C1404.
27. +-ATPase expression in human intestinal xenografts in vivo. Am. J. Physiol. Gastrointest. Liver Physiol. 286: G157-G165.
28. Resta-Lenert, S., J. Smitham & K.E. Barrett. 2005. Epithelial dysfunction associated with the development of colitis in conventionally housed mdr1a-/-mice. Am. J. Physiol. Gastrointest. Liver Physiol. 289: G153-G162.
29. Panwala, C.M., J.C. Jones & J.L. Viney. 1998. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, imdr 1a, spontaneously develop colitis. J. Immunol. 161: 5733- 5744.
30. Ho, G.T., F.M. Moodie & J. Satsangi. 2003. Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut 52: 759-766.
31. Ho, G.T., E.R. Nimmo, A. Tenesa, et al. 2005. Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. Gastroenterology 128: 288-296.
32. Ho, G.T., N. Soranzo, E.R. Nimmo, et al. 2006. ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach. Hum. Mol. Genet. 15: 797-805.
33. Ho, G.T., D.R. Gaya & J. Satsangi. 2005. Multidrug resistance (MDR1) gene in inflammatory bowel disease: a key player? Inflamm. Bowel. Dis. 11: 1013- 1019.
34. Resta-Lenert, S. & K.E. Barrett. 2005. An estrogen receptor-beta (ER-beta) agonist ameliorates disease in the murine mdr1a -/- colitis model. Gastroenterology 128: A76.
35. Resta-Lenert, S. & K.E. Barrett. 2006. Antibiotic versus probiotic treatments in the mdr1a -/- mouse model of colitis. FASEBJ. 20: A1270.
36. Dunne, C., L. Murphy, S. Flynn, et al. 1999. Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. Antonie van Leeuwenhoek 76: 279-292.
37. Shanahan, F. 2000. Probiotics and inflammatory bowel disease: is there a scientific rationale? Inflammatory Bowel Diseases 6: 107-115.